drugset / Trial / NCT06691217
Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis
Phase 2
Recruiting
120 enrolled
Massachusetts General Hospital
Broad Institute of MIT and Harvard · collabNational Institutes of Health (NIH) · collabYale University · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary goal of this clinical trial is to test the hypothesis that the drug canakinumab (anti-IL-1B monoclonal antibody) decreases vascular inflammation when used by people with a history of coronary artery disease, including those with and without clonal hematopoiesis driven by mutations in TET2.
Timeline
- Start
- 2026-03-24
- Primary completion
- 2029-01-01
- Completion
- 2030-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Canakinumab | Monoclonal antibody | 150 mg | — |